AI-informed AdaptiveFlow redefines large-scale cloud computing for drug discovery

AdaptiveFlow is a novel AI-based platform that enables ultra-large virtual screenings of billions of drug-like molecules at a 1,000-fold reduction in computational cost, setting a new benchmark for cloud-based drug discovery with linear scaling up to 5.6 million CPUs. It has demonstrated success in identifying potent inhibitors for challenging cancer targets such as PARP1 and FSP1, improving both efficiency and access in drug discovery.

This Wire brief sits within Fusion42's coverage of Drug Discovery, AI Infrastructure and Cloud Infrastructure.